Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 23Ovarian Neoplasms 19Triple Negative Breast Neoplasms 17Endometrial Neoplasms 16Lung Neoplasms 15Parkinson Disease 4, Autosomal Dominant Lewy Body 12Fallopian Tube Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 4Melanoma 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Peritoneal Neoplasms 2Pathologic Complete Response 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Advanced Solid Tumour 2

Interventions

Cisplatin 6Paclitaxel 4pembrolizumab 3Fluorouracil 3Carboplatin 3tislelizumab 2Taxes 2Radiotherapy 2Oxaliplatin 2Leucovorin 2Irinotecan 2Injections 2Capecitabine 2130-nm albumin-bound paclitaxel 2spartalizumab 1lenvatinib 1durvalumab 1cixutumumab 1apatinib 1Tegafur 1Surgical Procedures, Operative 1Saline Solution 1Radiation 1Levoleucovorin 1Laparoscopy 1Histamine H2 Antagonists 1Histamine Antagonists 1Fulvestrant 1Docetaxel 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Paclitaxel × 30 days × Clear all
NCT07621601 2026-06-02

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Hansoh BioMedical R&D Company

Phase 3 Not yet recruiting
494 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06535607 2026-05-26

eVOLVE-02

AstraZeneca

Phase 2 Recruiting
257 enrolled
GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡